Immune checkpoint inhibitors, including anti-programmed cell death-1 (PD-1) and anti-PD-1 ligand (PD-L1) antibodies, have exhibited remarkable efficacy in some advanced cancers [93,94]. This evidence concerns the gene CD274 and cancer.